Deverra Therapeutics - Crunchbase Company Profile & Funding

Q: Who invested in Deverra Therapeutics?

Deverra Therapeutics has 2 investors including Andy Hill Cancer Research Endowment (CARE) Fund And 5AM Ventures.

Q: How much funding has Deverra Therapeutics raised to date?

Deverra Therapeutics has raised obfuscated.

Overview

Deverra Therapeutics

Total Funding

obfuscation

Growth Score

Heat Score

Company Performance Metrics

Score

Trend

About These Metrics

AI Content may contain mistakes and is not legal, financial or investment advice.

Learn more.

Growth Score - The measure of growth based on company activity, operational metrics, and investments

Growth Trend - The change in the growth score over the given time period

Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity

Heat Trend - The change in the heat score over the given time period

Recent Milestones

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

See more interactive data and historical milestones on desktop for the best experience

About Deverra Therapeutics

CB Rank

36061

Deverra Therapeutics is a biotechnology company that develops allogeneic cellular immunotherapies.

Founded

obfuscation

Private

Equity Crowdfunding

Seattle, Washington, United States

11-50

www.deverratx.com/

Biotechnology

Clinical Trials

Medical

Funding Rounds

Equity Crowdfunding

OBF

obfuscation

Grant

OBF

obfuscation

Pre-Seed

OBF

obfuscation

Key People

Colleen Delaney: Founder & Chief Scientific Officer, EVP of Research and Development
Past Role: Nohla Therapeutics, Founder and Chief Medical Officer
Michael Yurkowsky: Chief Executive Officer & Board Member

Details

Legal Name

Deverra Therapeutics, Inc.

Operating Status

Active

Company Type

For Profit

Founders

Colleen Delaney

About the Company

Deverra Therapeutics is a biotechnology company that develops allogeneic cellular immunotherapies.

Phone Number

206.519.5300

Contact Email

info@deverratx.com

Diversity Spotlight

Women Founded

Predictions & Insights

Growth Insight

See this Growth Insight

Deverra Therapeutics is

Lorem

to be growing

Top Contributing Factors

Recently Raised Funding

Growth Prediction

See this Growth Prediction

Top Contributing Factors

Growth Insight

Products & Services

Dilanubicel

A hematopoietic stem and progenitor cell immunotherapy for newly diagnosed acute myeloid leukemia (AML) patients, used as an adjuvant to standard chemotherapy to improve remission rates.

DVX201 (Natural Killer Cell Therapy)

An unmodified natural killer (NK) cell therapy used to treat relapsed/refractory AML, high-risk myelodysplastic syndromes (MDS), and to boost immunity against viral infections like COVID-19.

Research & Development

Deverra Therapeutics is

obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated

...

Unlock More with Crunchbase Pro

Full access to financial & funding data on unlimited profiles
Export up to 2k results/month for analysis
Track market signals on competitors, products, and R&D
Preview private company insights and predictions

Financials

Company Funding

Funding Rounds

Investors

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Equity Crowdfunding - Deverra Therapeutics	—	obfuscated obfuscation	—	Equity Crowdfunding
obfuscated obfuscation	Equity Crowdfunding - Deverra Therapeutics	—	obfuscated obfuscation	—	Equity Crowdfunding
obfuscated obfuscation	Equity Crowdfunding - Deverra Therapeutics	—	obfuscated obfuscation	—	Equity Crowdfunding
obfuscated obfuscation	Equity Crowdfunding - Deverra Therapeutics	—	obfuscated obfuscation	—	Equity Crowdfunding
obfuscated obfuscation	Equity Crowdfunding - Deverra Therapeutics	—	obfuscated obfuscation	—	Equity Crowdfunding

Funding Rounds

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Equity Crowdfunding - Deverra Therapeutics	—	obfuscated obfuscation	—	Equity Crowdfunding
obfuscated obfuscation	Equity Crowdfunding - Deverra Therapeutics	—	obfuscated obfuscation	—	Equity Crowdfunding
obfuscated obfuscation	Equity Crowdfunding - Deverra Therapeutics	—	obfuscated obfuscation	—	Equity Crowdfunding
obfuscated obfuscation	Equity Crowdfunding - Deverra Therapeutics	—	obfuscated obfuscation	—	Equity Crowdfunding
obfuscated obfuscation	Equity Crowdfunding - Deverra Therapeutics	—	obfuscated obfuscation	—	Equity Crowdfunding

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.

Investor Name	Lead Investor	Funding Round	Partners
Andy Hill Cancer Research Endowment (CARE) Fund	Yes	Grant - Deverra Therapeutics	—
Andy Hill Cancer Research Endowment (CARE) Fund	Yes	Grant - Deverra Therapeutics	—
Andy Hill Cancer Research Endowment (CARE) Fund	Yes	Grant - Deverra Therapeutics	—
Andy Hill Cancer Research Endowment (CARE) Fund	Yes	Grant - Deverra Therapeutics	—
Andy Hill Cancer Research Endowment (CARE) Fund	Yes	Grant - Deverra Therapeutics	—

Market Intelligence

People

View Profiles & Contacts

Headcount

11-50

Employee Profiles

Contacts

Employee Profiles

Colleen Delaney Founder & Chief Scientific Officer, EVP of Research and Development
Michael Yurkowsky Chief Executive Officer & Board Member
Barbra Keck Chief Financial Officer